Pharmacosmos calls off the hunt for investors

Pharmacosmos will make acquisitions without the use of new outside investors.

Family-owned Pharmacosmos has put an end to the search for investors and is instead focusing on creating financial reserves for future growth-generating acquisitions.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

Access all locked articles

Receive our daily newsletters

Access our app

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Former Demant Executive Vice President Arne Boye Nielsen was found responsible for creating an "unsafe psychological work environment" in an internal legal investigation. | Foto: Demant / Pr

Hearing health

Demant Foundation continues to work with ousted Demant executive

While the findings of a legal investigation were so serious that a Demant executive was fired, the majority owner of the hearing aid company subsequently elected him to several boards.

Sacked Demant executive receives USD 2.6 million golden handshake

Demant Board has "full confidence" in management's handling of unsafe work environment

For subscribers

Hearing health

CHMP recommends ten new medicines in June

For subscribers

Foto: George Frey/Reuters/Ritzau Scanpix

Pharma & biotech

Cosmetic Ozempic use under fire in EU amid drug shortages

Regulation

CHMP recommends conditional approval for Genmab and Abbvie's epcoritamab

For subscribers

Pharma & biotech

Novo to limit Wegovy’s China launch to avoid global disruption

Pharma & biotech

Analyst on Novo Nordisk writedown: "It is a reminder of the risks"

Novo Nordisk snaps up partner's hemophilia candidate and gene editing technology

A five-year collaboration is coming to an end as Novo Nordisk has decided to acquire a drug candidate and gene technology from its former partner.

For subscribers

Bavarian Nordic expects Jynneos to be fully effective against new mpox variant

Bavarian Nordic’s vaccine Jynneos is the only approved vaccine against the disease mpox.

Novo Nordisk implements hiring freeze in certain departments

Since 2021, Novo Nordisk has increased its number of employees by 20,000 to total 66,000.

For subscribers

Foto: Medwatch/photo by Ulrich Quistgaard

Genmab cancer drug approved in new indication in US

Epkinly has become the first and only subcutaneously administered T-cell engaging bispecific antibody approved in the US for the treatment of this patient population.

Novo Nordisk blood pressure candidate ends in USD 817m flop

Novo Nordisk acquired ocedurenone from KBP Biosciences in 2023.

"We're not just talking about an alternative to GLP. We actually believe the data is so strong that we have reason to believe that petrelintide could become the backbone of obesity treatment if we succeed," says CEO Adam Steensberg. | Foto: Stine Bidstrup

Zealand Pharma sitting pretty after "probably one of Europe's strongest capital raises ever"

The development of the obesity drug petrelintide must be accelerated now, says CEO Adam Steensberg.

For subscribers

Novo Nordisk implements hiring freeze in certain departments

Since 2021, Novo Nordisk has increased its number of employees by 20,000 to total 66,000.

For subscribers

Novo Nordisk does not have enough capacity to meet the demand for its products. | Foto: Gregers Tycho

Pharma & biotech

Media: Novo Nordisk in talks to buy factory

The price for the factory is estimated to be around USD 216 m and the deal is expected to close by the end of August.

For subscribers

Pharma & biotech

Analyst on Novo Nordisk writedown: "It is a reminder of the risks"

On Wednesday, Novo Nordisk made a write-down of DKK 5.7bn (USD 817m) after a failed study.

Adam Steensberg, CEO, Zealand Pharma | Foto: Stine Bidstrup

Pharma & biotech

Zealand sells USD 1 billion in shares to fund new obesity drugs

Zealand’s shares have climbed 138 percent this year.

For subscribers

Hearing health

Demant Foundation continues to work with ousted Demant executive

While the findings of a legal investigation were so serious that a Demant executive was fired, the majority owner of the hearing aid company subsequently elected him to several boards.

For subscribers

Pharma & biotech